LONDON, Dec 9 (Reuters) - Roche ROG.VX expects to announce whether or not it will continue developing experimental diabetes drug taspoglutide when it presents full-year financial results in early February, the Swiss drugmaker said on Thursday.
Many analysts believe the drug, which was licensed from France’s Ipsen (IPN.PA), is likely to be dropped due to adverse reactions among some patients in clinical tests. Roche suspended dosing in a late-stage trial in September. [ID:nN10269225]
“It’s fair to say the hurdles are high,” Roche’s head of investor relations Karl Mahler told an R&D meeting in London.
Roche had previously said it would make a decision on taspoglutide by the end of 2010. Mahler said the plan was now to communicate the decision alongside the results, which are tentatively scheduled for Feb. 2. (Reporting by Ben Hirschler)